Fortrea Raised Guidance. It Also Took a $558 Million Eraser to Its Backlog.

A stock that ran 36% into the print gave back a tenth of it — and the mid-teens margin roadmap management promised for 'the second half of the year' quietly lost its date.

FTRE · Earnings Call · 2026-10-29

A 36% run into a ten-day wobble

Fortrea's tape is a battleground, not a compounder. The shares ran 36% in the ninety trading days into this call, peaked at $25.88 on October 28 — the day before the print — and closed 10.6% below that high on the news. Zoom out and the whole history is still a bruise: -27.7% since June 2023, 42.6% below the April 2024 peak, with a 78% collapse followed by a 323% recovery in between. When a stock triples off the floor and then sells off on an earnings day, the market has already written the upside case for you; the report's job is to either confirm it or hand back some of the run. The headline numbers were genuinely better. Revenue of $691.5 million fell 1.4% year-over-year but rose 2.0% sequentially; adjusted EBITDA of $58.0 million was up 14.4%, with the margin at 8.4% versus 7.2% a year ago. Net income flipped to a $0.6 million profit from a $15.9 million loss, and management raised the midpoint of full-year revenue ($2.665–2.690 billion) and adjusted EBITDA ($210–218 million). That last bit is why the stock had run. But the last filed quarter shows how far the underlying business still has to travel: revenue of $678 million in the June quarter, down 16% from its 2022 peak, an operating margin of 2.2% and a net margin still marginally negative. The re-rating was to 0.6x revenue from a 0.16x trough. That is a recovery multiple being paid in advance.

The $558 million eraser

Here is the number the sell-side zeroed in on. Backlog went from $7.8 billion in Q2 to $7.3 billion, and inside that move sat a $558 million cumulative adjustment — roughly 7% of the opening balance — which management explicitly excluded from the reported 1.12x book-to-bill. New CFO Jason Knoblauch, on his first call in the seat, described it as

It is a mix of both inactive study dynamics as well as what we internally will call not to deliver dynamics within parts of the portfolio as well.
Jason Knoblauch, Chief Financial Officer · 2026-10-29

Translation: some trials have gone quiet, and some scope will simply never be delivered. Eric Coldwell of Baird pushed, noting this was “more than you were indicating in the past” — Eric Coldwell, Analyst · 2026-10-29 and that prior commentary had pointed to a low-to-mid single-digit percentage impact. Knoblauch conceded the obvious: “our work only completed on the assessment in Q3” — Jason Knoblauch, Chief Financial Officer · 2026-10-29. A new CFO marking the book is not sinister, but it is a change in the quality of the backlog number investors had been underwriting. The related tell is cancellations. Two quarters ago the language was pristine — “we've actually continued to see historic low levels and cancellation trends” — Jill McConnell, Chief Financial Officer · 2026-02-26 — and this quarter it was “within normal bounds albeit slightly elevated” — Jason Knoblauch, Chief Financial Officer · 2026-10-29, bundled with negative contract amendments and the newly-coined inactive study problem. Slightly elevated is still fine. The direction of travel is not. What genuinely did improve is cash. Net DSO collapsed to 15 days from 33 a year ago and 20 in Q2, driving $52.5 million of quarterly free cash flow and $47.4 million for the nine months versus a $33.3 million outflow last year. Free cash flow is no longer the problem. Leverage is: net debt of $845.7 million, 3.9x, improved 1.4 turns in twelve months but still heavy against $886 million of effective net cash and 80.7% liabilities-to-assets. The Worldwide Clinical Trials Early Phase deal adds about 0.25 turns.

The cost lever is retired. The growth lever is not yet engaged.

The strategic pivot on this call is explicit and easy to miss. After a year of profitable growth being framed as a cost story, Anshul Thakral declared the cost work done: “The major actions to better align our cost structure with the scale of the business are largely complete.” — Anshul Thakral, Chief Executive Officer · 2026-10-29 Check the company's own keyword history: 2026Q1 was led by net savings and cost optimization. Neither appears anywhere near the top of this quarter's list. In their place: compensation investment — a self-inflicted ~200 basis point gross margin headwind the CFO volunteered — and favorable business mix. Margin expansion is now a revenue-and-mix story or it is nothing. That makes the missing Investor Day a real signal. In February, Thakral said he wanted “mid-teens is where a pure-play CRO like ours is... That is our goal” — Anshul Thakral, Chief Executive Officer and Director · 2026-02-26, and in May the CFO promised the venue: “We talked to you guys last quarter about an Investor Day, we're thinking... in the second half of the year, and that will be the place for us to really lay out more detail about what that margin progression would look like.” — Jill McConnell, Chief Financial Officer · 2026-05-05 We are now nine weeks from year-end, and the only event on the calendar is a Jefferies fireside chat on November 17. The mid-teens target was restated as "true north" — with no date, no bridge, and no venue. When a company stops scheduling the meeting where it promised to prove the math, that is information.

What actually has to do the work

The bull case now rests on mix and volume, and there is a coherent version of it. Early Phase Services is the second-ranked theme of the quarter: more than 570 beds, a 300-bed Texas network, an in-house bioanalytical lab in Austin, and a sales cycle management describes as six weeks to six months with studies that "burn faster." That is the right asset for a company that needs revenue conversion, not just awards. China is the second leg — Fortrea pitches itself as an at-scale player serving Chinese biotech companies going global, and management argues the COINS Act conversation does not touch service providers. And the demand read is no longer hedged. In July it was “I remain cautiously optimistic” — Anshul Thakral, Chief Executive Officer · 2026-07-29; now Thakral says the sector is “starting to get into the middle of this market recovery” — Anshul Thakral, Chief Executive Officer · 2026-10-29, with biotech bookings up nearly double digits in 2026 and biopharma RFPs arriving. The Biopharma recovery is corroborated by the broader tape of reporters in this window — Lilly, Merck, Bristol, Biogen, Novartis, GSK all shipping pipeline and launch news — which is precisely the spending that becomes CRO awards with a lag. AI literacy rounds out the pitch: 95% of colleagues using AI weekly, a CRA mobile app in 49 countries, shortlisted for a Scrip award. The problem is that book-to-bill was 1.12x — identical to the trailing twelve months and below the 1.13x of a year ago. Guidance implies a sequential revenue step-down in Q4 on working days. The recovery is real in the pipeline. It is not yet real in the P&L, the backlog just got marked down 7%, and the stock is priced for the version where it is. Watch service fee revenue growth, backlog conversion above 9%, and whether an Investor Day gets a date before the year does.